Credit Suisse analyst Dan Leonard notes that Exact Sciences has announced its long-awaited BLUE-C data readout for Cologuard 2.0. Compared to its case/control data presented at 2022 American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, the cancer sensitivity/specificity performance were largely similar, but advanced adenoma detection rate was worse. Credit Suisse continues to believe Exact Sciences’ stock reflects its durable Cologuard value and maintains a Neutral rating with a price target of $75.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS: